• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas

byAndrew Bishara
December 27, 2013
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD Sisyphus

1. Patients with previously platinum-sensitive ovarian cancer showed no increase in progression-free survival or overall survival when randomized to two years Erlotinib treatment as compared to observation.

2. Post-hoc stratification of patient subgroups by age, stage, type of first-line chemotherapy, and response type to chemotherapy failed to show any group-specific advantage in either study groups.

Evidence rating Level: 1 (Excellent)

Study Rundown: This study, led by the European Organisation for Research and Treatment of Cancer- Gynaecological Cancer Group, is the first to inspect the effectiveness of a receptor tyrosine kinase inhibitor as maintenance therapy in patients who have had progression-free survival (PFS) after initial platinum-based chemotherapy. They showed that there was no difference in PFS nor overall survival (OS) for patients randomized to either Erlotinib (Tarceva) or observation. While the treatment period was designed to be two years, the median duration of Erlotinib treatment was 244 days and 107 patients (25.8%) stopped treatment due to severe adverse effects, primarily diarrhea or rash. Interestingly, while positive flourescent in-situ hybridization EGFR status had worst OS as compared to negative EGFR status (46.1 vs 67.0 months; HR, 1.56; 95% CI, 1.01 to 2.40; P=0.044) overall, there was no correlation between EGFR status and PFS, OS, and withdrawal from treatment due to adverse effects within the Erlotinib treatment arm itself. Erlotinib has been shown to have only modest success in treating non-small cell lung cancer. This study also reiterates the difficulty of finding a prognostic biomarker, as EGFR mutational status did not correlate to treatment response. Another limitation of this trial was that it was not placebo controlled, a decision that was not addressed by the authors.

Click to read the study in JCO

Relevant reading: Tyrosine kinase inhibitors as targets for cancer therapy

RELATED REPORTS

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

2 Minute Medicine Rewind, May 16

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

In-Depth [randomized-controlled study]: This study was a phase III randomized controlled trial that included 835 patients from 125 institutions in 10 countries. Patients with stage II-IV ovarian epithelial cancers who previously responded to platinum-based chemotherapy were randomized to either two year treatment with the receptor tyrosine kinase inhibitor, Erlotinib (n=420), or observation (n=415). The primary endpoint was PFS and secondary endpoints were OS, toxicity, incidence of rash, and quality of life. The median progression free survival (PFS) in the Erlotinib arm as compared to the observation arm were 12.7 and 12.4 months, respectively (stratification-adjusted HR, 1.05; 95% CI, 0.90 to 1.23; P=0.525) while the overall survial (OS) were 50.8 and 59.1 months, respectively (HR, 0.99; 95% CI, 0.81 to 1.20; P=0.903). Patients were stratified by FIGO stage, institution, age (>65 versus <65 years old), type of first-line therapy, and clinical response to first-line therapy.  The analysis was performed according to intention-to-treat and the median follow-up time was 51 months.  Survival was approximated using the Kaplan-Meier method and the durability of treatment response was analyzed using forest plots with heterogeneity tests.  Quality of life measures were limited by low compliance (<50% by the second year).

By Khang T. Dinh

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: cancerchemotherapyErlotiniboncologyplatinum-sensitive ovarian epithelial carcinomassurvival
Previous Post

Partial meniscectomy not superior to sham surgery for meniscal tear

Next Post

Elderly anemic patients at higher risk of postoperative mortality after vascular procedures

RelatedReports

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Image-guided percutaneous drainage of pericardial effusions is safe and effective
Weekly Rewinds

2 Minute Medicine Rewind, May 16

May 16, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Next Post
Soaring rates of peripheral artery disease, now over 200 million cases worldwide

Elderly anemic patients at higher risk of postoperative mortality after vascular procedures

Classics Series, Landmark Trials in Medicine

MMR vaccine not associated with autism [Pediatrics Classics Series]

Discharge diagnoses in the E.R. cannot retrospectively identify non-emergent visits

Prolonged exposure therapy more effective for sexual abuse-related PTSD

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.